Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression

Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with few therapeutic targets and rare effective treatments. Over 90% of PDAC tumors bear a Kras mutation, and the single-site mutation G12D (Kras(G12D)) is most prevalent. Methods: Here, we applied the CRISPR-CasRx system...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wang, Li, Hao, Liu, Xiyu, Zhang, Jianping, zhang, Wuhu, Li, Tianjiao, Liu, Liang, Yu, Xianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545986/
https://www.ncbi.nlm.nih.gov/pubmed/33052229
http://dx.doi.org/10.7150/thno.46642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545986/
https://www.ncbi.nlm.nih.gov/pubmed/33052229
http://dx.doi.org/10.7150/thno.46642

Ejemplares similares